Artivion Inc (Artivion), formerly CryoLife Inc, manufactures, processes and distributes medical devices and implantable human tissues utilized in cardiac and vascular surgeries for patients with aortic conditions. Its product portfolio comprises aortic stent grafts, surgical sealants, On-X mechanical heart valves and associated surgical products, and implantable cardiac and vascular human tissues.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Artivion has been actively involved in research and development initiatives to identify market opportunities for new products and services and to expand the use of their current products and services. The company's R&D strategy involves allocating resources among its core market areas based on potential market size, estimated development time and cost, and expected efficacy for any possible product or service offering. It also seeks to license non-core products or applications to corporate partners for further development or seek funding from outside sources. Artivion is also involved in acquiring or licensing additional strategically complementary products or technologies from third parties to supplement its product lines. The company is currently developing and investigating several new products and technologies and changes and enhancements to its existing products and services. The research and development department of Artivion Inc is responsible for managing the company's R&D activities. This department researches various projects and also sponsors research projects at universities and clinics. It also conducts preclinical and clinical studies at universities, medical centers, hospitals, and other third-party locations under contract with the company. The clinical research department collects and maintains clinical data on the use and effectiveness of their products and services, which is used to gain regulatory approvals and to inform third parties of the benefits of their products and services. Artivion is seeking regulatory approval for BioGlue in China. It is conducting a post-approval study for the On-X aortic heart valve with reduced warfarin therapy, expected to continue through 2027. In FY2024, the company invested US$28.4 million in its research and development activities, which as a percentage of its revenue stood at 7.3%.